People with IgA nephropathy often struggle to find treatments that truly protect their kidneys. Two large randomized controlled trials, DAPA-CKD and EMPA-KIDNEY, now provide evidence that SGLT2 inhibitors help specific subgroups of these patients. These drugs are designed to lower blood sugar but also offer strong protection for the kidneys.
Beyond the big trials, other studies looking at real-world patients consistently showed meaningful reductions in proteinuria. This is a sign that the kidneys are filtering waste better. Observational data also demonstrated that kidney function trajectories stabilized, meaning the decline stopped or slowed down for those who took the medication.
However, the evidence is not complete. Disease-specific randomized trials remain limited, and mortality data specific to IgA nephropathy are scarce. Indirect evidence from broader kidney disease populations suggests biological plausibility for survival benefits, but direct proof for this specific condition is still missing. The consistent signals from randomized, observational, and mechanistic evidence support the role of these drugs as kidney-protective therapy, but more research is needed to confirm long-term survival benefits for this specific group.
